Latest News
Tarceva® (erlotinib) tablets
A therapeutic advance in the treatment of 2nd line NSCLC and 1st line pancreatic cancer
Tarceva monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Tarceva is also approved for the first-line treatment of locally advanced, unresectable or metastatic pancreatic cancer in combination with gemcitabine (chemotherapy).
Learn more about TarcevaRead full indication and safety information
See Tarceva Prescribing Information
Oncology
Because every day is precious for our patients
An important part of our mission is to improve upon the available treatment options for patients suffering from cancer with treatments such as our flagship product, Tarceva. OSI scientists are at the forefront of a paradigm-shifting movement toward molecular targeted and better tolerated therapies.
Access more information on our oncology programs
Diabetes & Obesity
Novel therapeutic approaches to tackling type 2 diabetes and obesity
We’re all about developing medicines that can improve the lives of patients and have potential drug candidates for type 2 diabetes and obesity, two areas with major unmet medical needs.
Access more information on our diabetes and obesity programs
* These websites are not endorsed by OSI, and OSI is not responsible for their content.
Diagnosed with Stage IV lung cancer, Mike is thankful to be able to spend time outside in the yard gardening.
Click here to watch the video
Full Prescribing Information
Now enrolling patients in a Phase III clinical trial testing Tarceva as an adjuvant therapy in patients who have undergone surgery for non-small cell lung cancer with EGFR-positive tumors.
Learn more about the RADIANT Study
OSI’s Oncology research team strives to be a world leader in the development of Molecular Targeted Therapies for the treatment of cancer through exploiting the science underpinning the Epithelial Mesenchymal Transition (EMT).
Learn more